A review of the current research on in vivo and in vitro detection for alpha-synuclein: a biomarker of Parkinson's disease

Anal Bioanal Chem. 2023 Apr;415(9):1589-1605. doi: 10.1007/s00216-023-04520-1. Epub 2023 Jan 23.

Abstract

Parkinson's disease is a health-threatening neurodegenerative disease of the elderly with clinical manifestations of motor and non-motor deficits such as tremor palsy and loss of smell. Alpha-synuclein (α-Syn) is the pathological basis of PD, it can abnormally aggregate into insoluble forms such as oligomers, fibrils, and plaques, causing degeneration of nigrostriatal dopaminergic neurons in the substantia nigra in the patient's brain and the formation of Lewy bodies (LBs) and Lewy neuritis (LN) inclusions. As a result, achieving α-Syn aggregate detection in the early stages of PD can effectively stop or delay the progression of the disease. In this paper, we provide a brief overview and analysis of the molecular structures and α-Syn in vivo and in vitro detection methods, such as mass spectrometry, antigen-antibody recognition, electrochemical sensors, and imaging techniques, intending to provide more technological support for detecting α-Syn early in the disease and intervening in the progression of Parkinson's disease.

Keywords: Detection methods; In vitro and vivo; Parkinson’s disease; α-Syn.

Publication types

  • Review

MeSH terms

  • Aged
  • Biomarkers
  • Humans
  • Neurodegenerative Diseases*
  • Parkinson Disease* / diagnosis
  • Tremor
  • alpha-Synuclein

Substances

  • alpha-Synuclein
  • Biomarkers